Key facts
- Stimusil’s last known valuation is $29.2M (Aug 2023).
- It has raised $10.3M across 3 recorded rounds; the latest was Seed Round ($600K) in Dec 2024.
- Notable investors include Toubkal Partners, Gen Ilac Ve Saglik, Northwestern University.
- Stimusil has filed 5 Form Ds with the SEC since 2022, most recently Mar 2025 ($600K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Stimusil
Funding rounds
3 roundsAbout Stimusil
Operator of a medical device company intended to develop proprietary methods for subdermal photobiomodulation. The company's devices are used to deliver stimulation subdermally, using patented technology to cross the melanin layer, enabling medical professionals to have safe and effective photobiomodulation therapy.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2021
- Employees
- 10
- Website
- stimusil.com/
- Ownership
- Privately Held (backing)
Stimusil doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Stimusil shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Stimusil in its N-PORT filings yet. We sweep new filings monthly.